Reference : Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Oncology
http://hdl.handle.net/2268/25869
Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung
English
Pequeux, Christel mailto [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Breton, C. [> > > >]
Hagelstein, M. T. [> > > >]
Geenen, Vincent mailto [Université de Liège - ULg > > Centre d'immunologie >]
Legros, Jean-Jacques mailto [Université de Liège - ULg > Département des sciences cliniques > Département des sciences cliniques >]
Nov-2005
Lung Cancer
Elsevier Ireland Ltd
50
2
177-188
Yes (verified by ORBi)
International
0169-5002
Clare
[en] lung ; small-cell lung carcinoma ; non-small-cell lung carcinoma ; oxytocin receptor ; vasopressin receptors ; endothelium
[en] In order to assess if oxytocin- and vasopressin-induced mitogenic effects detected on small-cell lung carcinoma (SCLC) cell lines could be transposed on primary SCLC, the aim of the present work was to identify mediators of these mitogenic actions on primary tumours samples. This was addressed on normal human lung tissue, on SCLC and on non-SCLC (NSCLC). Herein, we observe, in normal human lung, that OTR is colocalized with vascular endothelial cells of the lung and is not expressed by lung cells of epithelial nature. We detected mRNA amplification of V1aR, V2R and of a V2R variant. We observed that 86% of SCLC biopsies analyzed expressed at least the OTR and that 71% expressed the OTR, the V1aR and the V2R altogether. Comparatively, 50% of NSCLC biopsies tested expressed at least the OTR and 32% expressed the OTR, the V1aR and the V2R altogether. The occurrence of the V1bR/V3R is of 28 and 18% for SCLC and NSCLC, respectively. Nevertheless, for the SCLC biopsies analyzed in this study, V1bR/V3R expression correlates, in all cases, with the expression of all the other neurohypophysial peptide receptors. Our results suggest that neurohypophysial peptide antagonists may offer promise as a potential new therapeutic modality for the treatment of lung cancer expressing at least one of the neurhypophysial peptide receptor subtypes. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
http://hdl.handle.net/2268/25869
10.1016/j.lungcan.2005.05.027

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
OT_OTR.SCLC.pdfPublisher postprint199.41 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.